{"id":36039,"date":"2026-08-26T17:23:00","date_gmt":"2026-08-26T11:53:00","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=36039"},"modified":"2026-08-26T15:51:03","modified_gmt":"2026-08-26T10:21:03","slug":"rise-of-mrna-vaccines","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/rise-of-mrna-vaccines","title":{"rendered":"From COVID-19 to Seasonal Influenza: Is mRNA Vaccine Technology Entering Its Second Act?"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_85 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a92aae5e87be\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a92aae5e87be\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/rise-of-mrna-vaccines\/#The_Shot_Heard_Around_the_Pharmacy_Counter_What_mFLUSIVA_Actually_Changes\" >The Shot Heard Around the Pharmacy Counter: What mFLUSIVA Actually Changes<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/rise-of-mrna-vaccines\/#Why_Flu_Is_the_Ultimate_Proving_Ground_for_the_mRNA_Platform\" >Why Flu Is the Ultimate Proving Ground for the mRNA Platform<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/rise-of-mrna-vaccines\/#Chasing_a_Moving_Target_Can_mRNA_Finally_Outrun_the_Flu_Virus\" >Chasing a Moving Target: Can mRNA Finally Outrun the Flu Virus?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/rise-of-mrna-vaccines\/#Fifty_Sixty-Five_and_the_Fine_Print_Age-Stratified_Approval_as_the_New_Regulatory_Playbook\" >Fifty, Sixty-Five, and the Fine Print: Age-Stratified Approval as the New Regulatory Playbook<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/rise-of-mrna-vaccines\/#Reactogenicity_Public_Trust_and_the_Uphill_Battle_for_Annual_Uptake\" >Reactogenicity, Public Trust, and the Uphill Battle for Annual Uptake<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/rise-of-mrna-vaccines\/#Beyond_Flu_How_mFLUSIVA_Could_Reshape_the_Broader_mRNA_Respiratory_Playbook\" >Beyond Flu: How mFLUSIVA Could Reshape the Broader mRNA Respiratory Playbook<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.delveinsight.com\/blog\/rise-of-mrna-vaccines\/#The_RSV_Battlefield_A_Preview_of_What_Flu_Could_Become\" >The RSV Battlefield: A Preview of What Flu Could Become<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.delveinsight.com\/blog\/rise-of-mrna-vaccines\/#The_Market_Opportunity_Sizing_Up_the_mRNA_Vaccines_and_Therapeutics_Boom\" >The Market Opportunity: Sizing Up the mRNA Vaccines and Therapeutics Boom<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/www.delveinsight.com\/blog\/rise-of-mrna-vaccines\/#The_Verdict_Second_Act_Not_Encore\" >The Verdict: Second Act, Not Encore<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>In August 2026, the U.S. FDA approved <strong>mFLUSIVA (mRNA-1010)<\/strong>, Moderna&#8217;s mRNA-based seasonal influenza vaccine, for adults aged 50 and older, the first flu shot in history built on the same messenger-RNA platform that powered the COVID-19 response. It is, by Moderna&#8217;s own count, the company&#8217;s fourth approved U.S. product, joining <strong>Spikevax, mNEXSPIKE, and mRESVIA<\/strong> on pharmacy shelves.<\/p>\n\n\n\n<p>That&#8217;s a headline. But the more interesting story sits underneath it: mRNA technology, once treated as a pandemic-era emergency tool, is now being asked to prove itself in the far less forgiving world of routine, seasonal, annually repeated vaccination. Flu shots don&#8217;t get emergency authorizations or global political urgency behind them; they compete every single autumn against decades-old egg-based vaccines, price-sensitive payers, and a public that has grown more skeptical of mRNA, not less, since 2021.<\/p>\n\n\n\n<p>So the real question isn&#8217;t whether mFLUSIVA got approved. It&#8217;s whether this approval marks the start of mRNA&#8217;s &#8220;second act&#8221;, its transition from crisis technology to durable, multi-disease commercial platform spanning flu, COVID-19, and RSV, and reshaping how the entire <a href=\"https:\/\/www.delveinsight.com\/blog\/respiratory-syncytial-virus-treatment\">respiratory vaccine market<\/a>, and the broader mRNA vaccines and therapeutics market, gets built over the next decade.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-the-shot-heard-around-the-pharmacy-counter-what-mflusiva-actually-changes\"><span class=\"ez-toc-section\" id=\"The_Shot_Heard_Around_the_Pharmacy_Counter_What_mFLUSIVA_Actually_Changes\"><\/span><strong>The Shot Heard Around the Pharmacy Counter: What mFLUSIVA Actually Changes<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>mFLUSIVA&#8217;s approval wasn&#8217;t a smooth, uneventful process, and that friction is exactly why it matters. The FDA initially declined to file Moderna&#8217;s application in February 2026, and the vaccine only reached approval after the agency&#8217;s Vaccines and Related Biological Products Advisory Committee unanimously recommended it, the panel&#8217;s first review of a new vaccine application in years, clearing the way for a Prescription Drug User Fee Act decision that ultimately arrived just ahead of the 2026\u20132027 flu season.<\/p>\n\n\n\n<p>The clinical case behind it is genuinely strong. In the pivotal <strong>FLUENT trial<\/strong>, a randomized, 40,000-plus-participant study spanning multiple countries, mFLUSIVA delivered 26.6% relative vaccine efficacy over a standard-dose comparator, with 27.4% efficacy in adults 65 and older That&#8217;s not a marginal win, it&#8217;s a meaningfully better outcome for a population that, in a recent U.S. flu season, accounted for 57% of hospitalizations and 71% of deaths despite representing a much smaller share of the population.<\/p>\n\n\n\n<p><strong>Why this approval is structurally different from a COVID-19 EUA:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>It&#8217;s a full Biologics License Application, not an emergency authorization, the regulatory bar most Americans associate with &#8220;real&#8221; vaccines.<\/li>\n\n\n\n<li>It had to win against entrenched, high-dose and adjuvanted flu vaccine incumbents that seniors already trust.<\/li>\n\n\n\n<li>It had to survive a political environment openly hostile to mRNA; the approval arrived amid continued public friction over mRNA vaccines from Health and Human Services leadership.<\/li>\n<\/ul>\n\n\n\n<p>That combination, clinical superiority plus regulatory friction plus political headwinds, is precisely why mFLUSIVA functions as a stress test for the entire mRNA vaccine category, not just a single product launch.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"454\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/mFLUSIVA-Development-Timeline-1024x454.webp\" alt=\"\" class=\"wp-image-36042\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/mFLUSIVA-Development-Timeline-1024x454.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/mFLUSIVA-Development-Timeline-300x133.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/mFLUSIVA-Development-Timeline-150x67.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/mFLUSIVA-Development-Timeline-768x341.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/mFLUSIVA-Development-Timeline-1536x682.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/mFLUSIVA-Development-Timeline.webp 1920w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-why-flu-is-the-ultimate-proving-ground-for-the-mrna-platform\"><span class=\"ez-toc-section\" id=\"Why_Flu_Is_the_Ultimate_Proving_Ground_for_the_mRNA_Platform\"><\/span><strong>Why Flu Is the Ultimate Proving Ground for the mRNA Platform<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-pipeline-insight\">COVID-19<\/a> gave mRNA technology its debut. Influenza gives it something arguably tougher: a recurring, high-stakes performance review. Unlike a novel pandemic pathogen, flu vaccines must be reformulated almost every single year to chase a moving target of circulating strains, selected by health authorities months in advance of flu season. Traditional egg-based manufacturing is slow and inflexible; strain selection has to happen early because production takes months, which sometimes means the vaccine and the actual circulating strain are already a step out of sync by the time flu season peaks.<\/p>\n\n\n\n<p>This is precisely the kind of problem mRNA technology was designed to solve. If a platform can reliably outperform decades-old flu vaccine science on efficacy, as mFluSiva&#8217;s trial data suggests, it builds a credibility bridge for mRNA&#8217;s broader ambitions across every seasonal respiratory virus that follows the same reformulate-and-repeat cycle.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-chasing-a-moving-target-can-mrna-finally-outrun-the-flu-virus\"><span class=\"ez-toc-section\" id=\"Chasing_a_Moving_Target_Can_mRNA_Finally_Outrun_the_Flu_Virus\"><\/span><strong>Chasing a Moving Target: Can mRNA Finally Outrun the Flu Virus?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Every flu season is, in effect, a forecasting exercise. Health authorities pick the strains they predict will circulate, months before the season starts, and when that prediction misses, vaccine effectiveness can collapse. This is where mRNA&#8217;s manufacturing speed becomes a genuine strategic advantage rather than a marketing talking point. Because mRNA vaccines are synthesized from a genetic sequence rather than grown in eggs or cell culture, the design-to-manufacture window for a newly targeted vaccine has reportedly been compressed from around six months down to two to three months. In a world where the World Health Organization&#8217;s strain recommendations sometimes prove wrong by the time flu season peaks, that speed advantage is not incremental; it&#8217;s potentially the difference between a well-matched vaccine and a poorly matched one.<\/p>\n\n\n\n<p>mFLUSIVA&#8217;s trivalent formulation encodes three separate influenza strain antigens aligned with current seasonal recommendations, illustrating how easily an mRNA construct can be updated relative to legacy platforms that require lengthy egg-adaptation and re-validation cycles. If mRNA developers can operationalize that speed advantage at scale, and do it consistently, season after season, strain-matching accuracy could become the platform&#8217;s signature commercial edge, not just a technical footnote.<\/p>\n\n\n\n<div dir=\"ltr\" align=\"left\">\n<table style=\"border-collapse: collapse; border: 1px solid #000000;\" border=\"1\"><colgroup><col width=\"174\"><col width=\"225\"><col width=\"225\"><\/colgroup>\n<tbody>\n<tr>\n<td style=\"text-align: center; border-width: 1px; border-color: #000000; background-color: #d7e9ff;\" colspan=\"3\">\n<p dir=\"ltr\"><strong>Traditional Egg-based Flu Vaccines vs. mRNA Flu Vaccines<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: center; border-width: 1px; border-color: #000000; background-color: #d7e9ff;\">\n<p dir=\"ltr\"><strong>Attribute<\/strong><\/p>\n<\/td>\n<td style=\"text-align: center; border-width: 1px; border-color: #000000; background-color: #d7e9ff;\">\n<p dir=\"ltr\"><strong>Traditional (Egg-Based)<\/strong><\/p>\n<\/td>\n<td style=\"text-align: center; border-width: 1px; border-color: #000000; background-color: #d7e9ff;\">\n<p dir=\"ltr\"><strong>mRNA-Based<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td style=\"border-width: 1px; border-color: #000000; background-color: #f8f8f8;\">\n<p dir=\"ltr\">Manufacturing Time<\/p>\n<\/td>\n<td style=\"border-width: 1px; border-color: #000000; background-color: #f8f8f8;\">\n<p dir=\"ltr\">6+ months (egg-based cultivation)<\/p>\n<\/td>\n<td style=\"border-width: 1px; border-color: #000000; background-color: #f8f8f8;\">\n<p dir=\"ltr\">As fast as 2&ndash;3 months (sequence-based)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td style=\"border-width: 1px; border-color: #000000; background-color: #f8f8f8;\">\n<p dir=\"ltr\">Strain-Update Flexibility<\/p>\n<\/td>\n<td style=\"border-width: 1px; border-color: #000000; background-color: #f8f8f8;\">\n<p dir=\"ltr\">Locked in early; hard to revise late<\/p>\n<\/td>\n<td style=\"border-width: 1px; border-color: #000000; background-color: #f8f8f8;\">\n<p dir=\"ltr\">Rapidly reprogrammable to new strains<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td style=\"border-width: 1px; border-color: #000000; background-color: #f8f8f8;\">\n<p dir=\"ltr\">Efficacy in Older Adults (50+)<\/p>\n<\/td>\n<td style=\"border-width: 1px; border-color: #000000; background-color: #f8f8f8;\">\n<p dir=\"ltr\">Established, moderate benchmark<\/p>\n<\/td>\n<td style=\"border-width: 1px; border-color: #000000; background-color: #f8f8f8;\">\n<p dir=\"ltr\">26.6% relative efficacy vs. standard-dose*<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td style=\"border-width: 1px; border-color: #000000; background-color: #f8f8f8;\">\n<p dir=\"ltr\">Reactogenicity<\/p>\n<\/td>\n<td style=\"border-width: 1px; border-color: #000000; background-color: #f8f8f8;\">\n<p dir=\"ltr\">Generally milder, well-established<\/p>\n<\/td>\n<td style=\"border-width: 1px; border-color: #000000; background-color: #f8f8f8;\">\n<p dir=\"ltr\">More frequent mild-to-moderate reactions<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Fifty_Sixty-Five_and_the_Fine_Print_Age-Stratified_Approval_as_the_New_Regulatory_Playbook\"><\/span><strong>Fifty, Sixty-Five, and the Fine Print: Age-Stratified Approval as the New Regulatory Playbook<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>One of the most commercially significant, and most underreported, details of the mFLUSIVA decision is how the FDA structured it. Rather than a single blanket approval, the agency granted a genuinely two-tiered pathway: full traditional approval for adults 50\u201364, and accelerated approval for adults 65 and older, contingent on a confirmatory postmarketing trial using a high-dose comparator.&nbsp;<\/p>\n\n\n\n<p>This matters for several reasons. It reflects important clinical nuance, as older adults, whose immune responses to vaccination may differ, also bear the greatest burden of flu-related mortality, prompting regulators to seek more definitive evidence in this population. It may also establish a precedent for age-stratified and indication-specific approval pathways, potentially influencing how future mRNA respiratory vaccines, including RSV and combination flu\/COVID vaccines, are evaluated. At the same time, it introduces commercial complexity, requiring manufacturers, healthcare providers, pharmacies, and marketers to communicate two distinct approval bases, full and accelerated, across overlapping age groups, a challenge that many traditionally approved egg-based competitors may not face.<\/p>\n\n\n\n<p>Notably, the FDA also required the older-adult trial to compare against a high-dose inactivated vaccine, the CDC&#8217;s preferred standard for that age group, rather than a standard-dose comparator, adding scrutiny that Moderna has said it expected under the agreed trial design. That regulatory rigor, while it slowed the timeline, also gives mFLUSIVA a more defensible evidence base heading into future indication expansions.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Reactogenicity_Public_Trust_and_the_Uphill_Battle_for_Annual_Uptake\"><\/span><strong>Reactogenicity, Public Trust, and the Uphill Battle for Annual Uptake<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Efficacy data alone won&#8217;t determine whether mFluSiva succeeds commercially. Two other factors will matter just as much: reactogenicity and public confidence. Clinical data indicates mFluSiva&#8217;s reactogenicity profile, soreness, fatigue, and similar short-term post-vaccination effects, is broadly consistent with other mRNA vaccines, but was reported more frequently than with comparator vaccines. For a demographic managing multiple chronic conditions, that&#8217;s not a footnote; it&#8217;s a real factor influencing whether someone rolls up their sleeve again next year.<\/p>\n\n\n\n<p>Layer onto a more complicated public trust environment. <a href=\"https:\/\/www.delveinsight.com\/blog\/mrna-based-vaccines-and-therapeutics\">mRNA vaccine technology<\/a> has become genuinely politically charged in the U.S., with senior health officials publicly questioning mRNA safety and even canceling federal funding tied to mRNA vaccine research in the past year. mFluSiva is entering the market with some of the most rigorous post-marketing study commitments the FDA has required for a vaccine of its kind, a reflection of just how much scrutiny mRNA products are facing right now. For annual flu vaccination, already a category with historically inconsistent uptake, mRNA technology will need to earn trust one flu season at a time, not just one clinical trial at a time.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Beyond_Flu_How_mFLUSIVA_Could_Reshape_the_Broader_mRNA_Respiratory_Playbook\"><\/span><strong>Beyond Flu: How mFLUSIVA Could Reshape the Broader mRNA Respiratory Playbook<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>mFLUSIVA doesn&#8217;t exist in isolation; it&#8217;s the third leg of a stool that already includes Spikevax\/mNEXSPIKE for COVID-19 and mRESVIA for RSV. Together, they represent Moderna&#8217;s attempt to own the entire respiratory-virus mRNA category, and the company has been vocal about pursuing combination shots (flu + COVID, and eventually flu + COVID + RSV) that could further consolidate that position. This is where the competitive map gets genuinely interesting, because RSV is the clearest parallel case study for how a crowded respiratory-vaccine market absorbs a new mRNA entrant, and it&#8217;s a market Sanofi cannot afford to sit out.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"The_RSV_Battlefield_A_Preview_of_What_Flu_Could_Become\"><\/span><strong>The RSV Battlefield: A Preview of What Flu Could Become<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The RSV vaccine market today is anchored by three approved, commercialized adult vaccines, <strong>GSK&#8217;s Arexvy, Pfizer&#8217;s Abrysvo, and Moderna&#8217;s mRESVIA<\/strong>, a set of Arexvy, Abrysvo, and mRESVIA RSV vaccines that between them illustrate exactly the protein-subunit-versus-mRNA dynamic now playing out in flu. GSK&#8217;s Arexvy, built on the RSVPreF3 pre-fusion protein platform, has held onto the largest share of the respiratory syncytial virus vaccine market, while Abrysvo has faced sharper swings in quarter-over-quarter sales.<\/p>\n\n\n\n<p>Sanofi&#8217;s position in this landscape is worth being precise about, because it differs structurally from GSK, Pfizer, and Moderna. Rather than a standalone adult RSV vaccine, Sanofi&#8217;s RSV drug franchise is currently anchored by <a href=\"https:\/\/www.delveinsight.com\/blog\/beyfortus-for-respiratory-syncytial-virus-treatment\">Beyfortus (nirsevimab)<\/a>, a long-acting monoclonal antibody co-developed with AstraZeneca for infant RSV prophylaxis, which real-world data has shown delivers a substantial reduction in RSV-related hospitalizations. Behind Beyfortus, the Sanofi RSV pipeline includes earlier-stage candidates such as SP0125, an intranasal vaccine aimed at extending protection across multiple RSV seasons, and SP0256, positioned as a future rival to Arexvy and Abrysvo in the older-adult segment. Taken together, this makes Sanofi RSV less a single-product story and more a multi-modality bet spanning monoclonal antibodies and next-generation vaccines, a useful reminder that when evaluating Sanofi competitors RSV marketed products and latest RSV competitors Sanofi marketed products, the comparison set spans vaccines and antibody prophylaxis, not vaccines alone.<\/p>\n\n\n\n<p>Why does this matter for flu? Because it previews the exact dynamic mRNA flu vaccines now face: an established, multi-player market where mRNA has to win share from trusted incumbents largely on efficacy and speed rather than novelty. The respiratory syncytial virus market, and its adjacent pediatric <a href=\"https:\/\/www.delveinsight.com\/report-store\/respiratory-syncytial-virus-rsv-market\">respiratory syncytial virus infection market<\/a>, served by monoclonal antibodies like Beyfortus rather than vaccines, shows that even a technically superior new entrant needs years to meaningfully shift prescriber and payer habits away from well-established respiratory syncytial virus marketed products.<\/p>\n\n\n\n<p>The strategic takeaway for the broader respiratory syncytial virus therapeutics market: mRNA&#8217;s credibility in flu will likely accelerate, or slow, how aggressively companies invest in mRNA-based RSV vaccines, combination shots, and next-generation mRNA products targeting other respiratory pathogens like hMPV and parainfluenza.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"411\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/Illustrative-Relationship-Vaccine-Confidence-Annual-Flu-Uptake-Analysis-1024x411.webp\" alt=\"Illustrative-Relationship-Vaccine-Confidence-&amp;-Annual-Flu-Uptake-Analysis\" class=\"wp-image-36055\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/Illustrative-Relationship-Vaccine-Confidence-Annual-Flu-Uptake-Analysis-1024x411.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/Illustrative-Relationship-Vaccine-Confidence-Annual-Flu-Uptake-Analysis-300x120.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/Illustrative-Relationship-Vaccine-Confidence-Annual-Flu-Uptake-Analysis-150x60.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/Illustrative-Relationship-Vaccine-Confidence-Annual-Flu-Uptake-Analysis-768x308.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/Illustrative-Relationship-Vaccine-Confidence-Annual-Flu-Uptake-Analysis-1536x617.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/Illustrative-Relationship-Vaccine-Confidence-Annual-Flu-Uptake-Analysis.webp 1920w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"The_Market_Opportunity_Sizing_Up_the_mRNA_Vaccines_and_Therapeutics_Boom\"><\/span><strong>The Market Opportunity: Sizing Up the mRNA Vaccines and Therapeutics Boom<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Behind every regulatory headline is a market thesis, and the numbers behind mRNA right now are hard to ignore. The global mRNA vaccines and therapeutics market was valued at roughly <strong>USD 71 billion<\/strong> in 2025 and is projected to grow significantly by 2034. Infectious disease indications still account for close to half of current market share, but oncology applications within the broader mRNA therapeutics market are forecast to grow even faster as clinical pipelines mature.&nbsp;<\/p>\n\n\n\n<p>A few structural trends stand out across these mRNA therapeutics market forecasts. The market is increasingly diversifying beyond infectious diseases, with oncology and immuno-oncology emerging as some of the fastest-growing application areas, even as infectious-disease vaccines continue to represent the largest share of current revenue. At the same time, advances in delivery technologies are expanding the potential of the platform, with ongoing research focused on next-generation lipid nanoparticles and self-amplifying RNA constructs designed to reduce effective dose requirements and potentially address reactogenicity concerns.&nbsp;<\/p>\n\n\n\n<p>Geographically, although North America currently accounts for the largest share of the <a href=\"https:\/\/www.delveinsight.com\/report-store\/mrna-vaccine-and-therapeutics-market\">mRNA vaccines and therapeutics market<\/a>, growing manufacturing investments in Asia-Pacific and government-backed RNA initiatives across other regions indicate that future growth is likely to become increasingly global. Meanwhile, the competitive landscape is also broadening. While Moderna and BioNTech\/Pfizer remain the most commercially advanced players, companies such as Sanofi, GSK, CureVac, and an expanding group of Asia-Pacific biotechs are strengthening their presence across the mRNA-based vaccines and therapeutics space, with influenza, RSV, and combination respiratory vaccines emerging as key areas of future competition.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"The_Verdict_Second_Act_Not_Encore\"><\/span><strong>The Verdict: Second Act, Not Encore<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>mFLUSIVA&#8217;s approval is not a repeat performance of the COVID-19 story; it&#8217;s a genuinely harder test, played out under normal regulatory scrutiny, against entrenched competitors, without the tailwind of a global emergency. That&#8217;s precisely why it matters. If mRNA flu vaccines can convert superior efficacy data into durable annual uptake, despite higher reactogenicity, political skepticism, and a crowded field, it strengthens the commercial case for mRNA across every other respiratory indication now in development, from <a href=\"https:\/\/www.delveinsight.com\/blog\/gsk-respiratory-syncytial-virus-vaccine\">next-generation RSV vaccines<\/a> to flu-COVID-RSV combination shots.<\/p>\n\n\n\n<p>The next twelve months, spanning a full flu season&#8217;s worth of real-world uptake data and a confirmatory trial in older adults, will tell us far more than the approval headline alone. But the direction of travel is clear: mRNA is no longer auditioning as a pandemic-response technology. It&#8217;s trying out for a permanent role on the respiratory vaccine stage, and flu, RSV, and whatever comes next are its second act.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/mrna-vaccine-and-therapeutics-market\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/mRNA-Vaccines-and-Therapeutics-Market-Outlook-1024x194.webp\" alt=\"mRNA Vaccines and Therapeutics Market Outlook\" class=\"wp-image-36044\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/mRNA-Vaccines-and-Therapeutics-Market-Outlook-1024x194.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/mRNA-Vaccines-and-Therapeutics-Market-Outlook-300x57.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/mRNA-Vaccines-and-Therapeutics-Market-Outlook-150x28.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/mRNA-Vaccines-and-Therapeutics-Market-Outlook-768x145.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/mRNA-Vaccines-and-Therapeutics-Market-Outlook-1536x291.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/mRNA-Vaccines-and-Therapeutics-Market-Outlook.webp 1584w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>In August 2026, the U.S. FDA approved mFLUSIVA (mRNA-1010), Moderna&#8217;s mRNA-based seasonal influenza vaccine, for adults aged 50 and older, the first flu shot in history built on the same messenger-RNA platform that powered the COVID-19 response. It is, by Moderna&#8217;s own count, the company&#8217;s fourth approved U.S. product, joining Spikevax, mNEXSPIKE, and mRESVIA on [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":36045,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[21112,19178,23083,21276,17615,20608,20609,22336,20610],"industry":[17226],"therapeutic_areas":[17231,17243],"class_list":["post-36039","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-beyfortus","tag-mrna-vaccine","tag-mrna-vaccine-technology","tag-mrna-vaccines-and-therapeutics","tag-respiratory-syncytial-virus","tag-respiratory-syncytial-virus-treatment","tag-respiratory-syncytial-virus-vaccines","tag-rsv-vaccine","tag-rsvpref3-vaccine","industry-medical-devices","therapeutic_areas-infectious-diseases","therapeutic_areas-respiratory-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.9 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Can mRNA Vaccines Drive the Next Vaccine Revolution?<\/title>\n<meta name=\"description\" content=\"In August 2026, the U.S. FDA approved mFLUSIVA (mRNA-1010), Moderna&#039;s mRNA-based seasonal influenza vaccine, for adults aged 50 and older.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/rise-of-mrna-vaccines\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Can mRNA Vaccines Drive the Next Vaccine Revolution?\" \/>\n<meta property=\"og:description\" content=\"In August 2026, the U.S. FDA approved mFLUSIVA (mRNA-1010), Moderna&#039;s mRNA-based seasonal influenza vaccine, for adults aged 50 and older.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/rise-of-mrna-vaccines\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-26T11:53:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/rise-of-mrna-vaccines.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"11 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Can mRNA Vaccines Drive the Next Vaccine Revolution?","description":"In August 2026, the U.S. FDA approved mFLUSIVA (mRNA-1010), Moderna's mRNA-based seasonal influenza vaccine, for adults aged 50 and older.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/rise-of-mrna-vaccines","og_locale":"en_US","og_type":"article","og_title":"Can mRNA Vaccines Drive the Next Vaccine Revolution?","og_description":"In August 2026, the U.S. FDA approved mFLUSIVA (mRNA-1010), Moderna's mRNA-based seasonal influenza vaccine, for adults aged 50 and older.","og_url":"https:\/\/www.delveinsight.com\/blog\/rise-of-mrna-vaccines","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2026-08-26T11:53:00+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/rise-of-mrna-vaccines.webp","type":"image\/webp"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.delveinsight.com\/blog\/rise-of-mrna-vaccines#article","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/rise-of-mrna-vaccines"},"author":{"name":"Sandeep Joshi","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"headline":"From COVID-19 to Seasonal Influenza: Is mRNA Vaccine Technology Entering Its Second Act?","datePublished":"2026-08-26T11:53:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/rise-of-mrna-vaccines"},"wordCount":2233,"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/rise-of-mrna-vaccines#primaryimage"},"thumbnailUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/rise-of-mrna-vaccines.webp","keywords":["Beyfortus","mRNA vaccine","mRNA Vaccine Technology","mRNA Vaccines and Therapeutics","Respiratory Syncytial Virus","Respiratory Syncytial Virus treatment","Respiratory Syncytial Virus Vaccines","RSV vaccine","RSVPreF3 vaccine"],"articleSection":["Articles"],"inLanguage":"en-US","copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/www.delveinsight.com\/blog\/#organization"}},{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/rise-of-mrna-vaccines","url":"https:\/\/www.delveinsight.com\/blog\/rise-of-mrna-vaccines","name":"Can mRNA Vaccines Drive the Next Vaccine Revolution?","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/rise-of-mrna-vaccines#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/rise-of-mrna-vaccines#primaryimage"},"thumbnailUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/rise-of-mrna-vaccines.webp","datePublished":"2026-08-26T11:53:00+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"In August 2026, the U.S. FDA approved mFLUSIVA (mRNA-1010), Moderna's mRNA-based seasonal influenza vaccine, for adults aged 50 and older.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/rise-of-mrna-vaccines"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/rise-of-mrna-vaccines#primaryimage","url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/rise-of-mrna-vaccines.webp","contentUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/rise-of-mrna-vaccines.webp","width":466,"height":284,"caption":"rise-of-mrna-vaccines"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/rise-of-mrna-vaccines-300x183.webp","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Beyfortus<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">mRNA vaccine<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">mRNA Vaccine Technology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">mRNA Vaccines and Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Respiratory Syncytial Virus<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Respiratory Syncytial Virus treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Respiratory Syncytial Virus Vaccines<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">RSV vaccine<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">RSVPreF3 vaccine<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Beyfortus<\/span>","<span class=\"advgb-post-tax-term\">mRNA vaccine<\/span>","<span class=\"advgb-post-tax-term\">mRNA Vaccine Technology<\/span>","<span class=\"advgb-post-tax-term\">mRNA Vaccines and Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">Respiratory Syncytial Virus<\/span>","<span class=\"advgb-post-tax-term\">Respiratory Syncytial Virus treatment<\/span>","<span class=\"advgb-post-tax-term\">Respiratory Syncytial Virus Vaccines<\/span>","<span class=\"advgb-post-tax-term\">RSV vaccine<\/span>","<span class=\"advgb-post-tax-term\">RSVPreF3 vaccine<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 3 days ago","modified":"Updated 3 days ago"},"absolute_dates":{"created":"Posted on Aug 26, 2026","modified":"Updated on Aug 26, 2026"},"absolute_dates_time":{"created":"Posted on Aug 26, 2026 5:23 pm","modified":"Updated on Aug 26, 2026 3:51 pm"},"featured_img_caption":"rise-of-mrna-vaccines","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/36039","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=36039"}],"version-history":[{"count":4,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/36039\/revisions"}],"predecessor-version":[{"id":36056,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/36039\/revisions\/36056"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/36045"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=36039"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=36039"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=36039"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=36039"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=36039"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}